Breast cancer data bonanza
At the annual San Antonio Breast Cancer Symposium, AstraZeneca and Daiichi yesterday presented data on their experimental drug, trastuzumab deruxtecan. The news was good: About 60.9% of the women tested — all of whom tested positive for the HER2 marker — saw their tumors shrink by at least 30%. As STAT's Matthew Herper explains, patients who received the drug survived for a median 21.9 months, compared to 17.4 months for those in the control group.
Meantime, adding tucatinib, a drug being developed by Seattle Genetics, to the older drug combination of Herceptin and Xeloda reduced the risk of death by 34% in advanced breast cancer.
Dr. Harold Burstein, from the Dana-Farber Cancer Institute, called the trastuzumab deruxtecan result “impressive,” saying it “far outpaces previous reports for agents in the setting of refractory disease.” But he warned that the 10% or 15% rate of pneumonitis, an inflammation of the lung, might be a roadblock for using the drug earlier in the disease.
Meantime, adding tucatinib, a drug being developed by Seattle Genetics, to the older drug combination of Herceptin and Xeloda reduced the risk of death by 34% in advanced breast cancer.
Dr. Harold Burstein, from the Dana-Farber Cancer Institute, called the trastuzumab deruxtecan result “impressive,” saying it “far outpaces previous reports for agents in the setting of refractory disease.” But he warned that the 10% or 15% rate of pneumonitis, an inflammation of the lung, might be a roadblock for using the drug earlier in the disease.
.png)
No hay comentarios:
Publicar un comentario